SBI

Biotech company CellsBin has announced a Series A funding round led by 108 BioCapital, with proceeds earmarked for advancing its rare-cell intelligence platform. The platform focuses on detecting and analyzing rare cells, a capability relevant to research and diagnostics in areas like oncology and rare disease. The funding signals continued investor interest in specialized cell-analysis technologies.